Home › Research › Drug development
Nuclear tau immunoreactivity in presenile dementia with motor neuron disease: a case report
Papasozomenos SC.. Clinical neuropathology, 1995-03-01
Topic: Brain proteins, microglia and lab models
We report for the first time localization of tau immunoreactivity with neuronal nuclei in an autopsy case of a 64-year-old white male with a 10-year history of presenile dementia with motor neuron disease. The anti-tau mAbs Tau-1, Tau-2, Tau-5 and PHF-1 and the anti-phosphoneurofilament mAb SMI-31, which crossreacts with tau, stained neuronal nuclei in neocortical pyramidal layer V or in layer III of primary motor cortex, in the periamygdaloid and entorhinal cortices, in pons and in a few paramedian neurons in dorsal medulla. The staining was excluded from nucleoli.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Papasozomenos, S. C. (1995). Nuclear tau immunoreactivity in presenile dementia with motor neuron disease: a case report. Clinical neuropathology.
Vancouver
Papasozomenos SC. Nuclear tau immunoreactivity in presenile dementia with motor neuron disease: a case report. Clinical neuropathology. 1995. PMID: 7606894.
BibTeX
@article{papasozomenos1995-7606894,
author = {Papasozomenos, S. C.},
title = {{Nuclear tau immunoreactivity in presenile dementia with motor neuron disease: a case report}},
journal = {Clinical neuropathology},
year = {1995},
pmid = {7606894}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- We report for the first time localization of tau immunoreactivity with neuronal nuclei in an autopsy case of a 64-year-old white male with a 10-year history of presenile dementia with motor neuron disease.
- The anti-tau mAbs Tau-1, Tau-2, Tau-5 and PHF-1 and the anti-phosphoneurofilament mAb SMI-31, which crossreacts with tau, stained neuronal nuclei in neocortical pyramidal layer V or in layer III of primary motor cortex, in the periamygdaloid and entorhinal cortices, in pons and in a few paramedian neurons in dorsal medulla.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 24 of the 58 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical neuropathology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1995 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 7606894) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 24 of the 58 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development
Also tagged “immunoreactivity”
5 studies in the library carry the topic tag “immunoreactivity”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.